脑内微量注射化学损毁法制备帕金森模型的技术改良
|
摘要
目的针对传统帕金森病模型制备方法进行合理改良提高模型成功率,减少不良反应。方法 43只Wistar大鼠分为传统组(n=20)与改良组(n=23),传统组采用经典的脑内微量注射6-羟基多巴,制备帕金森病化学损毁旋转模型,改良组对微量注射器预处理,封接经加热的注射电极,以减小微量注射器的注射直径。结果传统组术中出血比例为65%,改良组术中出血比例为0%,两者比较差异显著(P <0. 05);传统组术后死亡率为15%,改良组术后动物死亡率为0%,两者比较差异显著(P <0. 05);传统组模率制备成功率为52. 9%,而改良组模率制备成功率率为91. 3%,两者比较差异显著(P <0. 05)。结论应用改良的脑内微量注射方式制备帕金森病模型,可明显减少术中出血,降低实验动物死亡率,增加注射准确性进而大幅度提高模型制备的成功率。具有很好的应用和推广价值。
Objective To improve the preparation method of traditional Parkinson's disease model. Methods 43 rats were divided into traditional group( n = 20) and modified group( n = 23). The traditional group employed classical intracerebral microinjection of 6-hydroxydopa to prepare the chemical lesion rotation model of Parkinson's disease,and the modified group pretreated the microinjector and sealed the heated injection electrode to reduce the injection diameter of the microinjector. Results The proportion of intraoperative bleeding was 65% in the traditional group and 0% in the improved group,the difference was significant( P < 0. 05); the mortality rate was 15% in the traditional group and 0% in the improved group,the difference was significant( P < 0. 05); the success rate of the traditional group was 52. 9%,while the improved group was 91. 3%,the difference was significant( P < 0. 05). Conclusion Using the improved intracerebral microinjection method to prepare Parkinson's disease model can significantly reduce intraoperative hemorrhage,reduce the mortality rate of experimental animals,increase the accuracy of injection and greatly improve the success rate of model preparation. It has good application and promotion value.
Objective To improve the preparation method of traditional Parkinson's disease model. Methods 43 rats were divided into traditional group( n = 20) and modified group( n = 23). The traditional group employed classical intracerebral microinjection of 6-hydroxydopa to prepare the chemical lesion rotation model of Parkinson's disease,and the modified group pretreated the microinjector and sealed the heated injection electrode to reduce the injection diameter of the microinjector. Results The proportion of intraoperative bleeding was 65% in the traditional group and 0% in the improved group,the difference was significant( P < 0. 05); the mortality rate was 15% in the traditional group and 0% in the improved group,the difference was significant( P < 0. 05); the success rate of the traditional group was 52. 9%,while the improved group was 91. 3%,the difference was significant( P < 0. 05). Conclusion Using the improved intracerebral microinjection method to prepare Parkinson's disease model can significantly reduce intraoperative hemorrhage,reduce the mortality rate of experimental animals,increase the accuracy of injection and greatly improve the success rate of model preparation. It has good application and promotion value.
引文
[1]MARTNEZ-MARTNEZ A M,AGUILAR O M,ACEVE-DO-TRIANA C A.Meta-analysis of the relationship between deep brain stimulation in patients with Parkinson's disease and performance in evaluation tests for executive brain functions[J].Parkinsons Dis,2017,2017:9641392.
[2]LILL C M,KLEIN C.Epidemiology and causes of Parkinson's disease[J].Nervenarzt,2017,88(4):345-355.
[3]CACABELOS R.Parkinson's disease:from pathogenesis to pharmacogenomics[J].Int J Mol Sci,2017,18(3):551.
[4]BAE J R,KIM S H.Synapses in neurodegenerative diseases[J].BMB Rep,2017,50(5):237-246.
[5]TIEU K.A guide to neurotoxic animal models of Parkinson's disease[J].Cold Spring Harb Perspect Med,2011,1(1):a009316.
[6]BLANDINI F,ARMENTERO M T.Animal models of Parkinson's disease[J].FEBS J,2012,279(7):1156-1166.
[7]SANKHLA C S.Oxidative stress and Parkinson's disease[J].Neurol India,2017,65(2):269-270.
[8]BOVJ,PERIER C.Neurotoxin-based models of Parkinson's disease[J].Neuroscience,2012,211:51-76.
[9]MORIN N,JOURDAIN V A,DI PAOLO T.Modeling dyskinesia in animal models of Parkinson disease[J].Exp Neurol,2014,256:105-116.
[10]BLANDINI F,ARMENTERO M T,MARTIGNONI E.The6-hydroxydopamine model:news from the past[J].Parkinsonism Relat Disord,2008,14(Suppl.2):S124-S129.
[11]DEUMENS R,BLOKLAND A,PRICKAERTS J.Modeling Parkinson's disease in rats:an evaluation of 6-OHDA lesions of the nigrostriatal pathway[J].Exp Neurol,2002,175(2):303-317.
[2]LILL C M,KLEIN C.Epidemiology and causes of Parkinson's disease[J].Nervenarzt,2017,88(4):345-355.
[3]CACABELOS R.Parkinson's disease:from pathogenesis to pharmacogenomics[J].Int J Mol Sci,2017,18(3):551.
[4]BAE J R,KIM S H.Synapses in neurodegenerative diseases[J].BMB Rep,2017,50(5):237-246.
[5]TIEU K.A guide to neurotoxic animal models of Parkinson's disease[J].Cold Spring Harb Perspect Med,2011,1(1):a009316.
[6]BLANDINI F,ARMENTERO M T.Animal models of Parkinson's disease[J].FEBS J,2012,279(7):1156-1166.
[7]SANKHLA C S.Oxidative stress and Parkinson's disease[J].Neurol India,2017,65(2):269-270.
[8]BOVJ,PERIER C.Neurotoxin-based models of Parkinson's disease[J].Neuroscience,2012,211:51-76.
[9]MORIN N,JOURDAIN V A,DI PAOLO T.Modeling dyskinesia in animal models of Parkinson disease[J].Exp Neurol,2014,256:105-116.
[10]BLANDINI F,ARMENTERO M T,MARTIGNONI E.The6-hydroxydopamine model:news from the past[J].Parkinsonism Relat Disord,2008,14(Suppl.2):S124-S129.
[11]DEUMENS R,BLOKLAND A,PRICKAERTS J.Modeling Parkinson's disease in rats:an evaluation of 6-OHDA lesions of the nigrostriatal pathway[J].Exp Neurol,2002,175(2):303-317.